Help

Search Results

212 results

  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 01

    Cross-sectional surveys on the use of tobacco products in the general population and in users of IQOS in Germany, Italy, and London (2018-2020): introducing the study protocols

    SPONSIELLO-WANG Z.; LANGER P.; PRIETO L.; DOBRYNINA M.; SKIADA D.; CAMILLE N.; WEITKUNAT R.; LÜDICKE F.
    Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland
    Background: Philip Morris International (PMI) launched cross-sectional surveys in Italy, Germany, and London in March 2018 following the commercialization of a heat-not-burn tobacco product, IQOS. This publication introduces the study protocols....
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 02

    Quantification of nitrogen oxides in aerosol of heat-not-burn IQOS product and combination of aerosol collection with the aerosol generation for TSNA analysis

    BADER P.; DEBRICK A.; GAUTIER L.; RADTKE F.; HUNKELER P.; MATERA R.; REYREN C.; CRENNA M.; STOOP A.
    Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland
    Nitrogen oxides (NOx), nitrogen monoxide (NO), and tobacco-specific nitrosamines (TSNA) are compounds that are analysed in the mainstream aerosol of heat-not-burn tobacco products, such as IQOS. The purpose of this study was to develop and validate a...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 03

    Determination of nicotine, eugenol, menthol and aerosol formers in tobacco products and materials

    BELLO J.; D’AGOSTINO A.; JUVET-PECALVEL C.; NAGANATHAN K.; ROTA C.; GAUTIER L.; O’REILLY C.; DUPASQUIER N.; YERLY M.
    Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland
    The purpose of this study was to validate a unique method that simultaneously determines the concentration of nicotine, eugenol, menthol, and glycerin in Reduced-Risk Products tobacco products[1], and menthol and triacetin in materials. Analytes are...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 30

    Effects of exposure to e-cigarette aerosols compared with cigarette smoke on 3D human buccal and small airway cultures: a systems toxicology assessment

    ISKANDER A.(1); STEINER S.(1); MAJEED S.(1); KONDYLIS A.(1); XIANG Yang(1); ZANETTI F.(1); FRENTZEL S.(1); MARTIN F.(1); PEITSCH M.C.(1); DOSHI U.(2); McKINNEY W.J.(2); LEE K.M.(2); HOENG J.(1)
    (1) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (2) Altria Client Services LLC, Research, Development & Regulatory Affairs, Richmond VA, U.S.A.
    Considerable attention has been given toward the reduced risk potential of e-cigarettes (e-cigs). Most in vitro studies have focused on testing e-liquid formulations directly on submerged 2D cultures. Here, we examined the effects of exposure to the...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 48

    Six-month systems toxicology inhalation/cessation study in ApoE-/- mice to investigate cardiovascular and respiratory exposure effects of two reduced risk tobacco products compared with conventional cigarettes

    PHILLIPS B.(2); SZOSTAK J.(1); HO J.(2); GUEDJ E.(1); WONG Ee Tsin(2); TALIKKA M.(1); LEBRUN S.(1); TITZ B.(1); MARTIN F.(1); VUILLAUME G.(1); LEROY P.(1); IVANOV N.(1); VANSCHEEUWIJCK P.(1); PEITSCH M.C.(1); HOENG J.(1)
    (1) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (2) Philip Morris International Research Laboratories Pte. Ltd., (part of Philip Morris International group of companies), PMI R&D, Singapore
    Cigarette smoking causes adverse health effects that may occur shortly after smoking initiation and lead to the development of cardiovascular disease, respiratory disease (chronic obstructive pulmonary disease), and various cancers. To reduce the...
  7. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 54

    Patterns of use behaviors in a sample of Japanese heat-not-burn tobacco product (IQOS) users

    AFOLALU E.F.; LANGER P.; PRIETO L.; SKIADA D.; DOBRYNINA M.; SPONSIELLO-WANG Z.; WEITKUNAT R.; LÜDICKE F.
    Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland
    Innovative tobacco products are being developed with the potential to advance tobacco harm reduction efforts and reduce the risk of smoking-related diseases. Their potential beneficial public health impact depends upon smokers’ acceptance to switch...
  8. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 58

    Developing fit-for-purpose self-report instruments for assessing consumer responses to tobacco and nicotine products: the ABOUT Toolbox initiative

    CHREA C.(1); SPIES E.(1); AFOLALU E.F.(1); MAINY N.(1); GALLOT S.(1); BINGGELI P.(1); CLERC E.(1); WEITKUNAT R.(1); SALZBERGER T.(2); CANO S.(3); ACQUADRO C.(4); ARNOULD B.(4); LAMBERT J.(4); BRUNEL V.(4); MARCUCCILLI C.(4); ABETZ-WEBB L.(5); ROSE J.(5); FAGERSTRÖM K.(5)
    (1) Philip Morris Products S.A.(part of Philip Morris International group of companies), Neuchâtel, Switzerland; (2) University of Economics and Business, Vienna, Austria; (3) ScaleReport, Ltd, Stotfold, U.K.; (4) Mapi, an ICON plc Company, Lyon, France; (5) Patient-Centered Outcomes Assessments, Ltd, Macclesfield, Cheshire, U.K.; (6) Rose Research Center, Raleigh, NC, U.S.A.; (7) K. Fagerström Consulting AB, Vaxholm, Sweden
    Assessing the full potential of reduced risk products (RRP), for individual users and the population as a whole, requires the assessment of consumer perception and behavior associated with tobacco and nicotine products (TNP) with different exposure...
  9. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 61

    A 6-month inhalation study in Apoe-/- mice to investigate cardiovascular and respiratory exposure effects of e-vapor aerosols compared with cigarette smoke

    WONG Ee Tsin(1); SZOSTAK J.(2); KRISHNAN S.(1); TAN Wei Teck(1); SEOW E.(1); TENG C.(1); LEE K.M.(3); ZHANG Jingjie(3); McKINNEY W.J.(3); PEITSCH M.C.(2); VANSCHEEUWIJCK P.(2); HOENG J.(2)
    (1) Philip Morris International Research Laboratories Pte. Ltd., (part of Philip Morris International group of companies), PMI R&D, Singapore; (2) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (3) Altria Client Services LLC, Richmond, VA, U.S.A.
    Chronic exposure to cigarette smoke is a risk factor for the development and progression of cardiovascular disease and chronic obstructive pulmonary disease. Considerable attention has been given towards the potential reduced harm of e cigarettes (e...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 27

    Pharmacokinetics of nicotine following the controlled use of a prototype novel tobacco vapour product

    YUKI D.(1,2); SAKAGUCHI C.(1); KIKUCHI A.(1); FUTAMURA Y.(1)
    (1) Japan Tobacco Inc., R&D Group, Scientific Product Assessment Center, Yokohama, Kanagawa, Japan; (2) JT International S.A., Scientific & Regulatory Affairs, Geneva, Switzerland
    The objective of this clinical study was to investigate the pharmacokinetics of nicotine following the use of a prototype novel tobacco vapour (PNTV) product in comparison to a conventional cigarette (CC1). The study was conducted in Japanese healthy...